聚合内容 The Healthcare Sales & Marketing Network
Healthcare Sales & Marketing Network NewsFeed
更新时间: 59 分钟 13 秒 前

GE Healthcare Announces FDA Approval of SenoClaire, New Breast Imaging with 3D Tomosynthesis Solution

周三, 09/03/2014 - 15:19
WAUWATOSA, Wis.--(Healthcare Sales & Marketing Network)--GE Healthcare (GE) today announced the FDA approval of SenoClaire*, GE’s new breast tomosynthesis solution designed with a three-dimensional imaging technology. In collaboration with Massachusetts Ge...
Devices, Radiology, Oncology, FDA
GE Healthcare, SenoClaire, breast tomosynthesis, imaging

ProNAi Therapeutics, Inc. Names New President and Chief Executive Officer

周三, 09/03/2014 - 15:16
PLYMOUTH, Mich.--(Healthcare Sales & Marketing Network)--ProNAi Therapeutics, Inc., a developer of novel nucleic acid therapeutics, announces the appointment Nick Glover, Ph.D. as President and Chief Executive Officer. The company’s previous CEO, Mina Sooc...
Biopharmaceuticals, Personnel
ProNAi Therapeutics

SinuSys Corp. Names Robert Hoxie as Chief Commercial Officer

周三, 09/03/2014 - 15:14
PALO ALTO, Calif.--(Healthcare Sales & Marketing Network)--SinuSys Corp., an innovative sinus health company, today announced that Robert Hoxie has joined the company as chief commercial officer, effective September 1. Mr. Hoxie will provide strategic sale...
Devices, Personnel
SinuSys, Vent-Os, Sinus Dilation System

Intensity Therapeutics, Inc. Appoints Ian B. Walters M.D., MBA as Vice President and Chief Medical Officer

周三, 09/03/2014 - 15:12
WESTPORT, Conn.--(Healthcare Sales & Marketing Network)--Intensity Therapeutics, Inc., a privately-held specialty pharmaceutical company developing novel products to treat solid tumor cancers, announced today that Ian B. Walters M.D., MBA, has been appoint...
Biopharmaceuticals, Oncology, Personnel
Intensity Therapeutics, in situ chemovaccination

Voyager Therapeutics Appoints Steven Paul, M.D., to Chief Executive Officer

周三, 09/03/2014 - 15:10
Industry Veteran Brings More than 35 Years of Expertise in CNS Drug Discovery and Development CAMBRIDGE, Mass.--(Healthcare Sales & Marketing Network)--Voyager Therapeutics, a gene therapy company developing life-changing treatments for fatal and debili...
Biopharmaceuticals, Neurology, Personnel
Voyager Therapeutics

Eisai Sells U.S. Rights to Zonegran(R) (zonisamide) Capsules to Concordia Pharmaceuticals Inc.

周三, 09/03/2014 - 15:08
WOODCLIFF LAKE, N.J., Sept. 3, 2014 -- (Healthcare Sales & Marketing Network) -- Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., today announced it has entered into an agreement with Concordia Pharmaceuticals Inc. ("Concordia"...
Biopharmaceuticals, Acquisitions
Eisai, Concordia Pharmaceuticals, Zonegran, zonisamide

Nabriva Therapeutics Appoints Dr Colin Broom as Chief Executive Officer

周三, 09/03/2014 - 14:55
New US Subsidiary to be located in the Philadelphia Area VIENNA, September 3, 2014 -- (Healthcare Sales & Marketing Network) --Nabriva Therapeutics AG, a biotechnology company focused on developing pleuromutilins, a new class of antibiotics for the tre...
Biopharmaceuticals, Personnel
Nabriva Therapeutics, antibiotic, pleuromutilins

Boston Scientific Closes Acquisition Of Interventional Business Of Bayer AG

周二, 09/02/2014 - 13:19
MARLBOROUGH, Mass., Sept. 2, 2014 -- (Healthcare Sales & Marketing Network) -- Boston Scientific Corporation (BSX) closed on its previously announced agreement to purchase the Interventional business of Bayer AG. The acquisition enhances the ability of Bo...
Devices, Interventional, Mergers & Acquisitions
Boston Scientific, Bayer AG, AngioJet, Fetch 2, JetStream

Integra LifeSciences Announces Changes Within Its Orthopedics and Tissue Technologies Business

周二, 09/02/2014 - 13:15
PLAINSBORO, N.J., Sept. 2, 2014 -- (Healthcare Sales & Marketing Network) -- Integra LifeSciences Holdings Corporation (IART) today announced that it has made changes to the leadership of its Orthopedics and Tissue Technologies business. The new organizati...
Devices, Orthopaedic, Personnel
Integra LifeSciences

Clearside Biomedical, Inc. Completes $16 Million Series B Financing

周二, 09/02/2014 - 12:56
ALPHARETTA, Ga.--(Healthcare Sales & Marketing Network)--Clearside Biomedical, Inc., today announced the closing of a $16 million Series B financing. The financing included new investor RusnanoMedInvest (RMI) and existing investors Hatteras Venture Partner...
Biopharmaceuticals, Ophthalmology, Venture Capital
Clearside Biomedica

Sorin Group Announces First World Implant of CROWN PRT(TM) Heart Valve

周二, 09/02/2014 - 12:46
New stented aortic bioprosthesis with outstanding ease of use and performance successfully implanted in Austria MILAN--(Healthcare Sales & Marketing Network)--Sorin Group (SRN.MI), (Reuters Code: SORN.MI), a global medical company and a leader in the tr...
Devices, Cardiology
Sorin Group, CROWN PRT, aortic bioprosthesis, heart valve

Elekta’s Versa HD Radiation Therapy System Now Available for Treatment of Cancer Patients in Japan

周二, 09/02/2014 - 12:35
Linear accelerator receives clearance from country’s Ministry of Health, Labor and Welfare STOCKHOLM--(Healthcare Sales & Marketing Network)--Cancer care providers in Japan have the opportunity to strengthen their cancer treatment capacity with the rece...
Devices, Oncology, Regulatory
Elekta, Versa HD, linear accelerator, radiotherapy

GE Healthcare Announces European Union Approval of VIZAMYL(TM) (Flutemetamol (18F) Solution for Injection) for PET Imaging of Beta Amyloid Plaque in Suspected Alzheimer’s Disease

周一, 09/01/2014 - 18:43
PET Imaging Agent Receives Marketing Authorisation from the European Commission CHALFONT ST. GILES, England--(Healthcare Sales & Marketing Network)--GE Healthcare announced today that VIZAMYL™ (flutemetamol (18F) solution for injection) has received mar...
Biopharmaceuticals, Devices, Radiology, Oncology, Regulatory
GE Healthcare, VIZAMYL, Flutemetamol, Positron Emission Tomography

Covidien Acquires Venous Disease Treatment Developer Sapheon, Inc.

周四, 08/28/2014 - 16:34
Transaction expands Covidien’s market leading portfolio with next generation technology for treatment of varicose veins DUBLIN, Ireland--(Healthcare Sales & Marketing Network)--Covidien plc (COV) today announced that it has acquired Sapheon, Inc., a pri...
Devices, Mergers & Acquisitions
Covidien, Sapheon, VenaSeal, varicose veins

Armetheon Completes $7.0 Million Series A Financing

周四, 08/28/2014 - 16:31
Company poised to enter final pivotal trial for novel oral anti-coagulant MENLO PARK, Calif., Aug. 28, 2014 -- (Healthcare Sales & Marketing Network) -- Armetheon, Inc. (www.armetheon.com), a biopharmaceutical company focused on developing novel mid- t...
Biopharmaceuticals, Cardiology, Venture Capital
Armetheon, Tecarfarin, Vitamin K epoxide reductase

Isogenica Appoints New Chief Executive Officer

周四, 08/28/2014 - 16:27
CAMBRIDGE, England--(Healthcare Sales & Marketing Network)--Isogenica are pleased to announce the appointment of Dr. Chris Ullman as CEO with effect from September 29th 2014, following the decision by Dr. Kevin Matthews to leave Isogenica to join a publicl...
Biopharmaceuticals, Personnel
Isogenica

Ligand Partner GlaxoSmithKline Receives U.S. FDA Approval for Promacta(R)/Revolade(TM) For Use in Patients with Severe Aplastic Anemia

周三, 08/27/2014 - 14:14
The third labeled indication for the drug Represents a new first-in-class treatment option for SAA patient population with insufficient response to immunosuppressive therapy SAN DIEGO--(Healthcare Sales & Marketing Network)--Ligand Pharmaceuticals I...
Biopharmaceuticals, FDA
Ligand Pharmaceuticals, GlaxoSmithKline, Promacta, Revolade, eltrombopag

Brainlab: First Patient Treatment with Revolutionary New Radiosurgery Software for Multiple Brain Metastases

周三, 08/27/2014 - 13:54
Automated treatment planning software by Brainlab sets a new benchmark in consistency, conformity and treatment efficiency MUNICH, Germany--(Healthcare Sales & Marketing Network)--New Automatic Brain Metastases Planning* software by Brainlab has been cl...
Devices, Oncology, Neurosurgery
Brainlab, radiosurgery, Automatic Brain Metastases Planning

Bellicum Pharmaceuticals Secures $55 Million in Oversubscribed Series C Financing

周三, 08/27/2014 - 13:28
Investor syndicate includes leading biotech and mutual funds HOUSTON--(Healthcare Sales & Marketing Network)--Bellicum Pharmaceuticals, Inc., a biotechnology company focused on developing safer and more effective cellular immunotherapies, today announce...
Biopharmaceuticals, Venture Capital
Bellicum Pharmaceuticals

European Commission Approves Bristol-Myers Squibb’s Daklinza (daclatasvir) Across Multiple Genotypes for the Treatment of Chronic Hepatitis C Infection

周三, 08/27/2014 - 13:23
Daklinza, when used in combination with sofosbuvir, is an all-oral, once daily regimen that yields cure rates of up to 100% Daklinza + sofosbuvir offers potential cure for a broad range of EU HCV patients, including those with advanced liver disease, g...
Biopharmaceuticals, Regulatory
Bristol-Myers Squibb, Daklinza, daclatasvir, hepatitis C

Contact us     New York    l    Miami    l    Sao Paulo     l    Mexico DF    l    London    l    Hong Kong